Agenus Inc. Appoints New Chief Medical and Scientific Officers
Ticker: AGEN · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1098972
Sentiment: neutral
Topics: executive-appointment, personnel-change, biotech
TL;DR
Agenus Inc. beefs up R&D with new CMO & CSO appointments.
AI Summary
On June 11, 2024, AGENUS INC. announced the appointment of Dr. David E. Johnson as Chief Medical Officer and Dr. Robert J. T. Miller as Chief Scientific Officer. Both appointments are effective immediately and are part of the company's strategic expansion in its research and development efforts.
Why It Matters
The appointment of experienced medical and scientific leaders signals Agenus Inc.'s commitment to advancing its research pipeline, potentially impacting future drug development and market positioning.
Risk Assessment
Risk Level: medium — Appointments of key executives can signal strategic shifts, but the immediate impact on financial performance is not yet clear.
Key Players & Entities
- AGENUS INC. (company) — Registrant
- Dr. David E. Johnson (person) — Appointed Chief Medical Officer
- Dr. Robert J. T. Miller (person) — Appointed Chief Scientific Officer
- June 11, 2024 (date) — Date of earliest event reported
FAQ
What are the specific responsibilities of the newly appointed Chief Medical Officer and Chief Scientific Officer?
The filing states their appointments are part of the company's strategic expansion in research and development efforts, but does not detail specific responsibilities.
When were these appointments effective?
The appointments of Dr. David E. Johnson and Dr. Robert J. T. Miller were effective immediately as of June 11, 2024.
Does this filing include any information about the compensation for the new officers?
This filing indicates 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of compensation for the new officers are not provided within the provided text.
What is AGENUS INC.'s primary business sector?
AGENUS INC. is in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.
What is the company's principal executive office address?
The principal executive offices are located at 3 Forbes Road, Lexington, Massachusetts, 02421.
Filing Stats: 871 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2024-06-17 16:05:01
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share AGEN The Nasdaq
- $47.40 — common stock with an exercise price of $47.40 (after giving effect to Agenus's one-fo
- $11.80 — common stock with an exercise price of $11.80 (after giving effect to Agenus' one-for
Filing Documents
- agen-20240611.htm (8-K) — 40KB
- agen-ex99_1.htm (EX-99.1) — 16KB
- img250783414_0.jpg (GRAPHIC) — 2KB
- 0000950170-24-074231.txt ( ) — 172KB
- agen-20240611.xsd (EX-101.SCH) — 23KB
- agen-20240611_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release dated June 17, 2024
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 17, 2024 By: /s/ Christine M. Klaskin Christine M. Klaskin, VP Finance